Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × eprenetapopt × Gastrointestinal × Clear all

Phase

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1 Gastrointestinal 1 Dermatologic 1

Conditions

Esophageal Neoplasms 1

Interventions

Fluorouracil 143 Gemcitabine 138 Oxaliplatin 133 Capecitabine 132 Leucovorin 105 Irinotecan 99 Bevacizumab 91 Cetuximab 67 Cisplatin 65 pembrolizumab 60 Radiotherapy 60 Nivolumab 41 130-nm albumin-bound paclitaxel 40 Sorafenib 39 Docetaxel 34 Albumin-Bound Paclitaxel 30 Radiosurgery 28 Surgical Procedures, Operative 25 Paclitaxel 25 regorafenib 24 Erlotinib Hydrochloride 23 Panitumumab 22 Cyclophosphamide 20 Celecoxib 20 Trastuzumab 19 Radiation 18 Neoadjuvant Therapy 18 IFL protocol 18 atezolizumab 17 Sunitinib 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02999893 2021-12-13

APROC

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Terminated

Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡